Table 4.

ORs for associations between serum lipid levels and presence and extent of baseline acute prostate inflammation in REDUCE

Presence of acute inflammationExtent of acute inflammation
NoneAnyNoneModerate; <20% of coresSevere; ≥20% of cores
nnOR (95% CI)nnOR (95% CI)nOR (95% CI)
Total cholesterol
 <200 mg/dL1,06719511,0671251671
 200–239 mg/dL3,3645991.06 (0.89–1.27)3,3643981.08 (0.87–1.34)1951.04 (0.78–1.39)
 ≥240 mg/dL1,2192111.09 (0.87–1.35)1,2191501.18 (0.91–1.52)610.96 (0.67–1.39)
Ptrend0.6690.3130.655
LDL
 <130 mg/dL2,80252212,80235211651
 130–159 mg/dL1,6452750.97 (0.82–1.15)1,6451810.95 (0.78–1.16)911.00 (0.76–1.32)
 ≥160 mg/dL1,2032081.04 (0.86–1.25)1,2031401.04 (0.83–1.29)671.07 (0.78–1.46)
Ptrend0.5560.5840.670
HDL
 <40 mg/dL1,10521911,1051391791
 40–59 mg/dL3,4606220.92 (0.78–1.09)3,4604190.97 (0.79–1.19)1960.81 (0.62–1.07)
 ≥60 mg/dL1,0851640.79 (0.63–0.99)1,0851150.86 (0.66–1.13)480.66 (0.45–0.97)
Ptrend0.0710.2480.120
Triglycerides
 <150 mg/dL3,63964013,63941812151
 150–199 mg/dL1,0541811.00 (0.84–1.20)1,0541261.08 (0.87–1.34)540.87 (0.64–1.19)
 ≥200 mg/dL9571841.11 (0.92–1.33)9571291.20 (0.97–1.49)540.95 (0.69–1.30)
Ptrend0.2680.1180.884
  • NOTE: ORs were adjusted for age at baseline (continuous), race (white, non-white), geographic region (North America, Europe, other), BMI (continuous, log-transformed), smoking status (never, former, current), statin use (no, yes), and NSAID use (no, yes).